Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,644,695
-
Total 13F shares
-
42,358,020
-
Share change
-
+5,527,931
-
Total reported value
-
$221,955,861
-
Put/Call ratio
-
0.95%
-
Price per share
-
$5.24
-
Number of holders
-
60
-
Value change
-
+$29,996,377
-
Number of buys
-
40
-
Number of sells
-
10
Institutional Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q4 2023
As of 31 Dec 2023,
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,358,020 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Nantahala Capital Management, LLC, Vestal Point Capital, LP, Point72 Asset Management, L.P., CITADEL ADVISORS LLC, Samsara BioCapital, LLC, VR Adviser, LLC, Rosalind Advisors, Inc., PURA VIDA INVESTMENTS, LLC, and Ikarian Capital, LLC.
This page lists
60
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.